Duopharma Biotech Bhd (XKLS:7148) Cash-to-Debt : 0.48 (As of Sep. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Duopharma Biotech Bhd Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Duopharma Biotech Bhd's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.48.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Duopharma Biotech Bhd couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Duopharma Biotech Bhd's Cash-to-Debt or its related term are showing as below:

XKLS:7148' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12 Med: 0.49 Max: No Debt
Current: 0.48

During the past 13 years, Duopharma Biotech Bhd's highest Cash to Debt Ratio was No Debt. The lowest was 0.12. And the median was 0.49.

XKLS:7148's Cash-to-Debt is ranked worse than
61.83% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.945 vs XKLS:7148: 0.48

Duopharma Biotech Bhd Cash-to-Debt Historical Data

The historical data trend for Duopharma Biotech Bhd's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Duopharma Biotech Bhd Cash-to-Debt Chart

Duopharma Biotech Bhd Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

0.40

0.45

0.52

0.34

0.37

Duopharma Biotech Bhd Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															0.33	0.37	0.30	0.31	0.48

Competitive Comparison of Duopharma Biotech Bhd's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Duopharma Biotech Bhd's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Duopharma Biotech Bhd's Cash-to-Debt falls into.

Duopharma Biotech Bhd Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Duopharma Biotech Bhd's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	157.637	/	(135.081	+	296.522)
	=	0.37

Duopharma Biotech Bhd's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	281.884	/	(227.154	+	362.677)
	=	0.48

Duopharma Biotech Bhd (XKLS:7148) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Duopharma Biotech Bhd Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Duopharma Biotech Bhd's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Duopharma Biotech Bhd (XKLS:7148) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Duopharma Biotech Bhd (XKLS:7148) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, MYS, 41200

Website

https://www.duopharmabiotech.com

Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer and exporter of pharmaceutical products and medicines.

Duopharma Biotech Bhd (XKLS:7148) Headlines

No Headlines